Mark Dela Cruz

@MarkBelkinMD @jihohan2 @swatirao24 @PWard35

@MarkBelkinMD @ISHLT @MaryjaneFarrMD @AndrewJSauer @Nikhil15 @dranulala @rachkataria

Informal survey time: at your center, for heart transplant upgrades to Status 2, what is your default intraaortic balloon pump approach?:

Dr.@VeliKTopkaraMD presents a new renal risk score predicting AKI requiring dialysis after heart transplant. Derived from >15,000 UNOS patients (2018–2024) 🔺High-risk (score >6) → 24% dialysis, ↓ 5-yr graft survival 💡 May help to better individualize risks. #ISHLT2025

@Toyokazu_Endo @UofL_cts ask Does it matter where you live when it comes to 🫀transplant? 14 states with no HT center! Fewer pts being listed from these states. Outcomes equivocal but disparities exist! @erin_schumer

Oral Session 43: Heart to Heart: Navigating Policy, Allocation, and Utilization for Optimal Transplant Outcomes on now #ISHLT2025 @ISHLT

@kgrace_phil from @nyulangone discusses how donors initially consented as DCD but transition to DBD represent the highest area of growth in donor heart and lung, with 48hrs between consent to procurement being a time of great increase. Very provocative!

Are we all being too picky when it comes to increased LV wall thickness on donor hearts? Perhaps yes. Dr Christian O’Donnell @StanfordMed presents intriguing insights on how we might refine the process.

@LeivaOrly describes the @UChicagoMed @UChicagoCardio experience with bloodless heart transplantation. Feasible and safe at their center.

👑 The king under fire? In the SHORE registry, patients with abnormal DNIT (GEP↑ + dd-cfDNA↑) but negative EMB had worse outcomes, primarily driven by graft dysfunction. 💣 Is it time to dethrone EMB as the gold standard? #ISHLT2025 @NirUrielMD

What is the role of #Apixaban in #LVAD? @IanBHollis @ISHLT ⭐️Overview of prospective trials w/ no thrombotic events at 6 mo follow up and low bleeding events ⭐️Selection Criteria & Reversal Strategy being key components to consider

Dr. Katelynn Madill-Thomsen compares MMDx vs histology in >1,500 EMBs (INTERHEART + Trifecta-Heart): ⬆️ High discordance rate ⚖️ When MMDx and histology disagreed, DSA and dd-cfDNA aligned with MMDx 👉Histology may miss rejection, specially ABMR #ISHLT2025

@ChristianBenden @BostonChildrens @ishlt working to help solidify recommendations for these key transitions

@ChristianBenden @BostonChildrens Transitioning involves individualized assessment of physical/psychosocial and even peds/adult institutional challenges. Transition processes should be coordinated, collaborative, responsive and evaluated!

#ISHLT2025 - Symposium 46: Pediatric Pulmonary Hypertension: From Birth to Transition starting now!

@UniFAU and atrial flow regulators for severe PAH w syncope and postcapillary LV hypertension as a bridge to transplant

@UniFAU There may also be a role for implantable PA sensors…

@BostonChildrens Risk assessment is key in determining treatment strategies! Recommended algorithms differentiate between those with or without cardiopulmonary conditions.

Dr Mary Mullen @BostonChildrens discusses #pediatric PHTN. Most cases are 2/2 genetic variants, congenital ❤️ dz, and developmental 🫁 dz.

@nymedcollege Treatment strategies include iNO (lowers ECMO use), adult PH therapies adjusted to peds pts. Positive side is many cases resolves #pediatrics #pulmonaryhypertension

Dr Erika Rosenzweig @nymedcollege teaches us about the dx/rx of neonatal PH